The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.

导出 LinkOut

翻译打印收藏纠错

作者： Jiaxuan,Li ^[1] ; Xin,Wu ^[1] ; Tianchen,Chu ^[1] ; Xin,Tan ^[2] ; Shixin,Wang ^[1] ; Ruisi,Qu ^[1] ; Zhouqing,Chen ^[3] ; Zhong,Wang ^[4]

作者单位： Department of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China. ^[1] Department of Neurology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China. ^[2] Department of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China. zqchen6@163.com. ^[3] Department of Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China. wangzhong761@163.com. ^[4]

关键词 Batoclimab Efgartigimod FcRn inhibitors Myasthenia gravis Nipocalimab Rozanolixizumab

主题词重症肌无力(Myasthenia Gravis);人类(Humans);受体, Fc(Receptors, Fc);组织相容性抗原Ⅰ类(Histocompatibility Antigens Class I);随机对照试验(主题)(Randomized Controlled Trials as Topic)

DOI 10.1007/s00415-024-12247-x

PMID 38431900

发布时间 2024-07-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交